Consensus Novartis AG

Equities

NOVN

CH0012005267

Market Closed - Swiss Exchange Other stock markets 11:30:11 2024-04-19 am EDT			5-day change	1st Jan Change
85.53 ^CHF	+1.19%		-0.66%	+0.78%

Apr. 19	US FDA mandates label updates on CAR-T cancer therapies	RE
Apr. 18	NOVARTIS AG : UBS reiterates its Buy rating	ZD

Evolution of the average Target Price on Novartis AG

Price target over the last 5 years

History of analyst recommendation changes

3f.wcJOCCCONESbxz4BWzA-OGJE8TW-wuxTi2D8qEA0y3A.9ZIKYnf7VxDUpHtvbnpPcwQUwUPLt5kipiGX2Ql3viatkBtqQrlfday0XQ~57e0ad78ff62acfb91bf7663be23df26

Analyst Recommendations on Novartis AG

NOVARTIS AG : UBS reiterates its Buy rating	Apr. 18	ZD
NOVARTIS AG : Deutsche Bank maintains a Buy rating	Apr. 18	ZD
Trending : Novartis Begins Tender Offer for MorphoSys Shares	Apr. 11	DJ
NOVARTIS : UBS reiterates its recommendation on the stock	Apr. 11	CF
NOVARTIS AG : UBS remains its Buy rating	Apr. 10	ZD
NOVARTIS AG : Jefferies maintains a Buy rating	Apr. 04	ZD
NOVARTIS AG : UBS reiterates its Buy rating	Apr. 04	ZD
NOVARTIS AG : Gets a Neutral rating from JP Morgan	Apr. 03	ZD
NOVARTIS AG : Barclays gives a Sell rating	Mar. 28	ZD
NOVARTIS AG : Berenberg remains Neutral	Mar. 25	ZD
NOVARTIS AG : Buy rating from Deutsche Bank	Mar. 22	ZD
BMO Capital Initiates Novartis at Market Perform Rating With $114 Price Target	Feb. 26	MT
NOVARTIS : Novartis on course to set new highs	Feb. 20
Moody's Lifts Novartis' Ratings, Outlook on Solid Operating Performance	Feb. 16	MT
Novartis' Midterm Sales Growth Prospects Limited as Patent Expirations Loom, Berenberg Says	Feb. 14	MT
This time it's for real	Feb. 09
NOVARTIS AG : Receives a Buy rating from Deutsche Bank	Feb. 07	ZD
NOVARTIS : UBS remains Buy on the stock	Feb. 07	CF
NOVARTIS AG : Gets a Neutral rating from JP Morgan	Feb. 07	ZD
Swiss Market Index Blinks Red Amid Renewed Rate Jitters	Feb. 06	MT
NOVARTIS AG : Barclays remains a Sell rating	Feb. 06	ZD
North American Morning Briefing : Rate Doubts Keep Pressure on Stocks; More Earnings in Focus	Feb. 06	DJ
European Midday Briefing : Stocks Higher But Gains Capped On Rate Doubts	Feb. 06	DJ
NOVARTIS AG : Buy rating from UBS	Feb. 06	ZD
NOVARTIS AG : Jefferies reiterates its Buy rating	Feb. 05	ZD

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

94.11 USD

Average target price

106.1 USD

Spread / Average Target

+12.72%

High Price Target

121.5 USD

Spread / Highest target

+29.09%

Low Price Target

81.17 USD

Spread / Lowest Target

-13.74%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Novartis AG

UBS	Matthew Weston
DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
JEFFERIES	Peter Welford
JPMORGAN	Richard Vosser
BARCLAYS	Emily Field
BERENBERG	Kerry Holford
BMO Capital
alphavalue	Abhishek Raval
DZ BANK	Elmar Kraus
Kepler Capital Markets
Societe Generale
Redburn
Stifel Nicolaus
BNP Paribas
MORGAN STANLEY	Mark Purcell
Barrington Research
Credit Suisse
International Strategy & Investment Group
Morningstar
ODDO BHF
GOLDMAN SACHS	Keyur Parekh
DA Davidson
Zacks Equity Research
Bank of America Securities/Merrill Lynch
BERNSTEIN RESEARCH	Wimal Kapadia
Kepler Cheuvreux
Wolfe Research
AltaCorp Capital
DEUTSCHE BANK	Emmanuel Papadakis
HSBC
Exane BNP Paribas
Bryan, Garnier & Co.
Berenberg Bank
Deutsche Bank Securities
Moody's Investors Service
Dundee
Exane BNP
Bernstein
Argus
Cowen
BRYAN GARNIER	Eric Le Berrigaud
LIBERUM CAPITAL	Graham Doyle
BANK OF AMERICA (BOFA)	Graham Parry

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar